The mystery of Jemperli’s rectal cancer breakthrough
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Asco 2022 – investors clutch at the Tigit straws
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.
Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
Pressure piles up on pamrevlumab
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
It’s official: expect near-zero Aduhelm sales for the foreseeable future
Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?
Big pharma’s key second-quarter data
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.
